The interleukin 12 (IL-12) family is unique in having the only heterodimeric cytokines, including IL-12, IL-23, IL-27 and IL-35. This feature endows these cytokines with a unique set of connections and functional interactions not shared by other cytokine families. Despite sharing many structural features and molecular partners, cytokines of the IL-12 family mediate surprisingly diverse functional effects. Here we discuss the unique and unusual structural and functional characteristics of this cytokine family. We outline how cells might interpret seemingly similar cytokine signals to give rise to the diverse functional outcomes that characterize this cytokine family. We also discuss the therapeutic implications of this complexity.
r e v i e w
Among the vast array of bioactive cytokines, the interleukin 12 (IL-12) family is unique. This is the only family of heterodimeric cytokines, which endows them with several unique and distinctive features. This family also has many molecular and functional characteristics that provide unique opportunities for positive and negative feedback control, and some additional features may still be identified. Chainpairing promiscuity is a common feature of this family of heterodimeric cytokines, which includes IL-12, IL-23, IL-27 and IL-35 at present 1,2 (Box 1). Despite the many structural similarities of the cytokines and their receptors and downstream signaling components, they have very different biological activities that belie their common features. IL-12 and IL-23 are mainly proinflammatory and prostimulatory cytokines with key roles in the development of the T H 1 and T H 17 subsets of helper T cells, respectively [3] [4] [5] . Although IL-27 was initially thought to be a proinflammatory cytokine, with some subsequent observations supporting that view 6 , the consensus now is that IL-27 is an immunoregulatory cytokine [7] [8] [9] . IL-35, the most recently identified member of this family, is a potent inhibitory cytokine produced by populations of thymus-derived natural regulatory T cells (nT reg cells) 1, 10 . This establishes a functionally balanced dichotomy in this family, with IL-12 and IL-23 being positive regulators and IL-27 and IL-35 being negative regulators (Fig. 1) .
Here we discuss the implications of the unique structural and functional features of the IL-12 family of cytokines and how this leads to more control and crosstalk than is typically noted in other cytokine families. We will also discuss what remains to be determined and speculate on additional layers of complexity that may exist, and assess how these features may complicate the therapeutic targeting and use of this fascinating cytokine family. We will focus mainly on the molecular aspects of these cytokines and their effect on T cell differentiation, acknowledging that they also affect other cell populations and a wide variety of disease conditions, which has been discussed extensively elsewhere 1, 4, [11] [12] [13] [14] [15] [16] 
(Box 2).
Variations on a theme: pairing promiscuity Chain sharing is a key feature of the IL-12 family of cytokines and receptors 1,2 (Box 1 and Fig. 1 ). The cytokine β-chains are components of two cytokines, whereas at least one α-chain (p35) is also a constituent of two cytokines (IL-12 and IL-35). The rationale for this propensity is unclear. It could simply be expedient to create multiple biologically diverse moieties from the same building blocks. Alternatively, this could help maintain immune balance such that deletion or disruption of a single protein or gene removes positive and negative components from the immune repertoire. Although it may seem a sound argument in the case of p35 and IL-12Rβ2, which are components of IL-12 and IL-35 and their receptors, respectively, such logic breaks down in considering the consequences of losing the cytokine chains p40 and Ebi3 and the receptor component IL-12Rβ1, which would 'preferentially' affect one side of this immune equation (Fig. 1) .
Given such a propensity for chain sharing, perhaps other combinations, such as p40-p28 and Ebi3-p19, can serve physiologically relevant functions, or perhaps the α-and β-chains of the IL-12 family can pair with other relatives of the IL-6 superfamily of cytokines. Indeed, a published study has suggested that p28 (IL-30) can naturally pair with the cytokine-like factor CLF to generate a cytokine that regulates the activity of natural killer cells and T cells via the receptor IL-6Rα 17 , in contrast to the normal function of CLF when it is paired with the cytokine CLC to form a cytokine that mediates survival pathways in neurons 18 . A complete picture of all the physiologically relevant interactions could provide the important insight needed to complete this immunological 'jigsaw puzzle' .
A family of heterodimeric cytokines that share components might also provide additional intrinsic mechanisms for controlling cytokine r e v i e w secretion and stability. Interestingly, the pairing efficiency and ability of the individual components to be secreted alone or in combination with other cytokines are vastly different. For example, IL-12 and IL-23 are disulfide-linked heterodimers and are secreted efficiently, whereas IL-27 and IL-35 lack this disulfide linkage and pair poorly and thus are secreted in much lower amounts (especially IL-35) 2, [19] [20] [21] [22] . This raises the possibility that in cells that express multiple chains of the IL-12 cytokine family, such as activated dendritic cells, macrophages or B cells, the chains may compete for pairing and secretion. Given the apparent stability of IL-12 and IL-23, they may dominate over IL-27 or IL-35. Thus, more studies are warranted to determine if this competition dynamic does occur and, if so, whether it has a physiological effect. It is also curious that the two positive regulatory cytokines (IL-12 and IL-23) are disulfide linked, whereas the two negative regulatory cytokines (IL-27 and IL-35) are not. Whether this is coincidental or establishes a valid structure-function link remains to be determined.
In addition to their canonical function as heterodimers, some components of the IL-12 family can function autonomously as monomers or homodimers. For example, p28 alone, in the absence of its normal partner Ebi3, has been shown to bind to but not signal via the receptor chain gp130, thereby antagonizing signaling via the receptors for IL-6 and IL-27, limiting the production of IL-17 and IL-10, respectively, and inhibiting the formation of germinal centers and antibody production 23 . In contrast, there is no clear evidence suggesting that p19 or p35 can be secreted without a partner. Homodimers of p40 have been shown to antagonize IL-12-driven responses by competing for its binding to IL-12Rβ1 while retaining the ability to activate dendritic cells [24] [25] [26] [27] . Although Ebi3 can be secreted, the extent to which this occurs and its physiological effect(s) are unknown. Together such observations represent hints that monomers or homodimers of the IL-12 family could affect the function of their heterodimeric siblings and/or immune function in general, although more analysis is clearly required.
The chain-sharing theme also extends to receptor use, with several cytokines using the same receptor chains 1,2,28 (Box 1 and Fig. 1 ). For example, IL-12Rβ1 is a component of the receptors for IL-12 and IL-23, IL-12Rβ2 is used by IL-12 and IL-35, and gp130 is bound by IL-27 and IL-35. As these receptor chains are expressed as monomers and form dimers after ligation of cytokines, it remains unclear whether this receptor sharing creates competition for binding when cells are exposed to multiple cytokines of the IL-12 family. Given the fact that competition for binding to receptors is the paradigm under which p28 operates 23 , it is possible that this may also occur with the heterodimers, which would provide an additional level of immunoregulation. For example, could IL-27 and IL-35 compete for gp130, could IL-12 and IL-23 compete for IL-12Rβ1, or could IL-12 and IL-35 compete for IL-12Rβ2? Indeed, could p28 (IL-30) inhibit the binding of IL-35, given that it also uses gp130? 23, 29 An additional layer of complexity has been identified by the observation that IL-35 can also ligate and signal via gp130-gp130 and IL-12Rβ2-IL-12Rβ2 homodimers 29 . Although this seems to be a unique feature of IL-35 not shared by other members of the IL-12 cytokine family, it is not without precedent, as gp130 can also signal as a homodimer after ligation with IL-6-soluble IL-6Rα complexes or viral 31) . How this affects the function of IL-35 relative to the function of its siblings in the IL-12 family remains to be determined.
Box 1 Composition of the IL-12 family of cytokines and their receptors and signaling components
The heterodimeric cytokines of the IL-12 family consist of an a-chain (p19, p28 or p35) and a b-chain 1,2 (p40 or Ebi3; Fig. 1 ). The a-chains have a four-helix bundle structure characteristic of the IL-6 superfamily, to which the IL-12 family belongs. In contrast, the b-chains share homology with class I receptor chains for cytokines, such as IL-6Ra. The p40 chain can pair with p35 or p19 to form IL-12 or IL-23, respectively, whereas Ebi3 can pair with p28 or p35 to form IL-27 or IL-35, respectively 41, 51, 60, 71, 72 (Fig. 1) .
The receptor chains are also used by multiple cytokines 1,2 ( Fig. 1 71, 75 . In contrast, IL-27 uses gp130 and IL-27R (WSX-1) 76 , whereas IL-35 signals via gp130 and IL-12Rb2 (ref. 29) . IL-35 is unusual in that it can also signal via two additional receptor-chain compositions: gp130-gp130 and IL-12Rb2-lL-12Rb2 homodimers 29 .
Signaling via all of these receptors is mediated by members of the Jak-STAT family 28, 77, 78 ( Fig. 1 ). Jak2 and either Jak1 or Tyk2 seem to mediate phosphorylation of STAT proteins associated with receptors for cytokines of the IL-12 family. IL-12 mediates signaling via p-STAT4 (ref. 
npg r e v i e w
The lack of any cytokine-receptor structures for the IL-12 family represents a considerable gap in the understanding of how these cytokines initiate signaling. Plausible models have been proposed, based on the IL-6 structure, that follow the 'site 1-2-3' architectural paradigm 29, 32 (Fig. 2) . In this model, site 1 mediates interaction between the four-helix bundle α-chains and the soluble receptor β-chains. As discussed above, interactions with site 1 may be similar for IL-12, IL-23 and IL-27 but different for IL- 35 (ref. 22) . Interactions with site 3 seem to require an amino-terminal immunoglobulin domain, which would preclude binding by the receptor IL-27R (WSX-1) and IL-12Rβ1 and thus relegate their binding to site 2. Therefore, the receptors IL-12Rβ2, IL-23R and gp130 would probably mediate interactions of site 3 with IL-12, IL-23 and IL-27, respectively. However, the model for IL-35 is more complex, as it is the only cytokine that interacts with two receptor chains that each have amino-terminal immunoglobulin domains (IL-12Rβ2 and gp130) 29 . This raises the possibility that multiple hetero-or homodimeric interactions exist, which may explain how IL-35 can interact with multiple receptor compositions 29 . It is also possible that distinct interactions, with sites 2 and 3 or other regions, could lead to different signaling events that form the basis for the divergent proinflammatory versus anti-inflammatory outcomes produced by the IL-12 family of cytokines. In summary, an unprecedented level of internal regulation may occur in the IL-12 family due to the extensive known and potential chain sharing and interactions of cytokines and receptors. It is possible that the full complexity of this network remains to be fully realized.
IL-12 cytokines as immunological playmakers
In many ways, the IL-12 family of cytokines epitomizes the central tenet of immunoregulation. IL-12 and IL-23 are proinflammatory or prostimulatory cytokines, whereas IL-27 and IL-35 are inhibitory cytokines 1,3-5,7-10 (Box 2 and Fig. 1 ). This raises the possibility that there is an unappreciated spectrum of immune balance that is established by and in the IL-12 family of cytokines. This is affected by multiple positive and negative feedback loops and interactions that modulate many aspects of immune function 1, [3] [4] [5] [7] [8] [9] [10] (Fig. 3) . In addition to modulating the activity of many T cell populations, the IL-12 family has a substantial effect on the direction of immune responses and a wide variety of diseases by also controlling the development of many contrasting T cell populations. Many of the immunoregulatory Box 2 The IL-12 cytokine family 'resumé'
• IL-12 is a proinflammatory cytokine produced by dendritic cells, macrophages and B cells in response to microbial pathogens 36, 82 . A positive feedback loop is established whereby IL-12-induced production of IFN-g by T cells primes additional antigen-presenting cells for IL-12 production and facilitates T H 1 differentiation. IL-12 can also induce the production of IFN-g by natural killer cells.
• IL-23, like IL-12, is a proinflammatory cytokine that is also produced by activated dendritic cells and macrophages in response to microbial pathogens, which is enhanced by interactions between the costimulatory molecule CD40 and its ligand 4, 14, 83 . It also induces expression of IL-23R, which creates a positive feedback loop that enhances IL-23 expression. However, it differs from IL-12 in having a key role in T H 17 development by stabilizing IL-17 expression and the T H 17 phenotype, but it is not a differentiation factor for T H 17 cells 84 . In addition, IL-23 is critical for inducing a pathogenic phenotype in T H 17 cells.
• IL-27 is mainly an inhibitory cytokine but may have some prostimulatory functions 6, 7, 83, 85, 86 . IL-27 is often generated during the resolution phase of an autoimmune response by local antigen-presenting cells. Furthermore, diverse stimuli (including nT reg cells, IFN-b, ligands for Toll-like receptors, and statins) can induce IL-27 production by antigen-presenting cells and thereby limit the induction of inflammation 87, 88 . Although IL-27 alone has no apparent direct stimulatory properties, in combination with IL-12 and/or IL-2 it can induce IFN-g production by T cells and natural killer cells 41 . IL-27 can inhibit IL-2 production limiting the proliferation of nT reg cells and T cells, but IL-2 can antagonize those effects by inhibiting the expression of IL-27R (WSX-1) 37, 38 . IL-27 can inhibit the development of T H 17 cells and induce the development of an IL-10-producing Tr1 cell-like regulatory population, in part by inducting c-Maf [42] [43] [44] [45] . IL-27-induced c-Maf expression can also facilitate the development of follicular helper T cells via the induction of IL-21 and thereby modulates the development and function of B cells 86, 89 .
• IL-35 is a potent inhibitory cytokine produced by mouse and human T reg cell populations 1, 10 and is required for their maximal suppressive capacity 51, 63 . IL-35 suppresses T cell proliferation by inducing cell-cycle arrest in G1 phase without inducing apoptosis 51, 53, 90 . Like TGF-b and IL-10, IL-35 can elicit the development of iTr35 cells, a population of induced T reg cells that suppress via IL-35 but does not express Foxp3, IL-10 or TGF-b 53, 63 . Inhibition mediated by human and mouse nT reg cells converts the suppressed target T cell population into iTr35 cells, which contribute to the regulatory milieu in inflammatory sites 53, 63 . Several reports have also shown that IL-35 seems to serve an immunomodulatory role in a wide variety of disease conditions 53, [90] [91] [92] [93] [94] [95] [96] [97] . IL-35 may be most influential at sites of high inflammation and strong activation of nT reg cells. (Fig. 3) . In this context, it might be argued that the IL-12 family of cytokines has a greater effect on shaping immune responses than any other cytokine family.
In delineating the multiple layers of interaction and influence, it is helpful to examine the effect of the IL-12 family of cytokines on the differentiation of specific T cell subsets (Fig. 3) . Several IL-12 family cytokines affect T H 1 and T H 17 development. The ability of IL-12 to drive T H 1 development is well known, whereas T H 17 development is facilitated by IL-23. As would be expected, the effect of the IL-12 family on the development of helper T cells is governed to a large extent by regulated receptor expression. Naive T cells express IL-12Rβ1 and gp130 but not IL-12Rβ2, IL-23R or IL-27R (WSX-1) [33] [34] [35] . Although signaling via the T cell antigen receptor with costimulation by CD28 is sufficient to induce IL-12Rβ2, such expression is enhanced by IL-27, as well as IL-2, tumor-necrosis factor and interferon-γ (IFN-γ). In contrast, signaling via the T cell antigen receptor is not sufficient to induce IL-23R expression. Cytokines that induce activation of the transcription factor STAT3 are the most potent drivers of IL-23R expression. STAT3 and the transcription factor RORγt act together to transactivate IL-23 and IL-23R, thereby facilitating a positive feedforward loop that enhances the expression of IL-23R, IL-17 and IL-22 and stabilizes the T H 17 phenotype. In addition, IL-12 and IL-27 affect T H 17 development by inhibiting key transcription factors (RORγt and RORα) that induce T H 17 differentiation. Furthermore, IL-12 and IL-27 can act on differentiating T H 17 cells by regulating the expression of receptors for other members of the IL-12 family and making them responsive to inhibitory cytokines and thus inducing IFN-γ in developing T H 17 cells. Similarly, IL-12 can also enhance production of the IL-23 component p19 by antigen-presenting cells and thereby limit T H 1 development and favor T H 17 development 36 .
IL-27 can limit the development of helper T cells in general by blocking IL-2 production, which is required for early T cell proliferation 37, 38 (Fig. 3) . However, once IL-2 production is initiated, the influence of IL-27 can be curtailed by the IL-2-driven downregulation of IL-27R (WSX-1) 39, 40 . IL-27 was initially thought to be a prostimulatory cytokine by virtue of its capacity to enhance the production of IFN-γ in the presence of low concentrations of IL-12 (ref. 41) . However, the function of IFN-γ-or any cytokine, for that matter-can be greatly influenced by other cytokines secreted together with it. IL-27 is also a potent inducer of IL-10, which, in combination with IFN-γ, represses T H 17 cells and promotes Tr1 cells [42] [43] [44] [45] . This is also facilitated by the IL-27-mediated induction of STAT1, which blocks RORγt expression 46 and induction of the transcription factors c-Maf and AhR, the growth factor IL-21 and the costimulatory molecule ICOS; these act together to induce Tr1 differentiation 45 29 . Given the suppressive phenotype of IL-27, perhaps some of this activity is in fact mediated by greater sensitivity to IL-35.
Although IL-35 can inhibit the proliferation of T H 1 cells, it has no effect on the proliferation of T H 17 cells, which we speculate might be due to limited receptor expression. This may provide further insight into the resistance of T H 17 cells to nT reg cell-mediated suppression 10 . It has been suggested that IL-23 may also contribute to that resistance via γδ T cells, but the mechanism of this remains unclear 54 npg r e v i e w unpublished data). Given that IL-12 can induce IFN-γ, it is possible that IL-12 may also limit conversion into iTr35 cells indirectly. Cytokines of the IL-12 family can also affect T H 2 cells (Fig. 3) . Whereas IL-12 inhibits IL-4 production and antagonizes T H 2 responses 11 , IL-35 blocks T H 2 development by repressing IL-4 and the transcription factor GATA-3, thereby limiting the proliferation of T H 2 cells (V. Chaturvedi and D.A.A.V., unpublished data). IL-35 can also mediate the conversion of T H 2 cells into iTr35 cells, although this too can be blocked by IFN-γ.
Like the effects of cytokines of the IL-12 family on populations of effector cells, these cytokines can also affect the development, homeostasis and function of nT reg cells. These cells are very dependent on IL-2 for effective proliferation and homeostasis 55, 56 . IL-12 and IL-27 can limit IL-2 production and consequently negatively affect nT reg cells 38, [57] [58] [59] . Conversely, IL-35 has been suggested to enhance the proliferation of nT reg cells 60, 61 . As pretreatment of T cells with IL-27 or IL-2 before treatment with IL-35 upregulates IL-12Rβ2, this may also affect the sensitivity of these cells to . Although IL-23 is not known to affect nT reg cells, it can limit the development of induced T reg cells driven by transforming growth factor-β (TGF-β) 54 . In contrast, IL-27 and IL-35 can mediate the development of distinct populations of induced T reg cells that do not express the transcription factor Foxp3. For example, IL-27 can induce the development of an IL-10-producing Tr1-like population of regulatory cells [42] [43] [44] 62 , whereas IL-35 can induce the development of IL-35-producing iTr35 cells 53, 63 .
Together these observations clearly show that the IL-12 family of cytokines acts as the immunological playmaker, shaping immune responses by directly inducing the development of T cell subpopulations and altering the function and fate of many cell populations that dictate disease outcome.
Appearances can be deceiving: divergent signaling output
The structural and functional observations noted above raise an important question: how do cells mediate divergent outcomes in response to seemingly similar signals generated by common signaling components? The importance of this question is emphasized by the fact that there are about 40 cytokines that signal through receptors that use a selection of only four kinases of the Jak family and seven STAT proteins 28 . There is considerable overlap in Jak-STAT use in the IL-12 family of cytokines, with all the receptors signaling via Jak2 and three of the four receptors using STAT4 (Box 1 and Fig. 1 ). These cytokines clearly mediate different downstream consequences and thus these signals must be interpreted differently.
Insight into one possible mechanism has been provided by analysis of signaling through the receptor for IL-35. IL-35 signals via STAT1 and STAT4 to drive an inhibitory program, whereas IFN-γ and IL-12 in combination induce activation of the same STAT proteins yet drive a prostimulatory program. The key distinguishing feature is the generation of STAT1-STAT4 heterodimers after ligation of the receptor for IL-35 that does not occur after combinatorial treatment with IFN-γ and IL-12 (ref. 29) . Furthermore, STAT1-STAT4 heterodimers, but not homodimers of STAT1 or STAT4, bind to consensus STATbinding sites in the promoters of Ebi3 and Il12a and mediate IL-35 production. Why STAT1-STAT4 heterodimers are generated only after ligation by IL-35 remains to be determined, but this could be due to the proximity of the phosphorylation of STAT1 to the phosphorylation of STAT4 that favors heterodimer formation. Indeed, the distribution of the receptors for IFN-γ and IL-12 may not be uniform and is altered after T cell activation, which suggests that these receptors might even be actively segregated as a mechanism for preventing the formation of STAT1-STAT4 heterodimers [64] [65] [66] .
Alternatively, IL-35 quantitatively promotes the generation of almost equal amounts of phosphorylated STAT1 (p-STAT1) and p-STAT4, which promotes heterodimerization and thus leaves little free phosphorylated STAT proteins for homodimerization. Given that the consensus STAT-binding motif (TTC-N 2-5 -GAA, where 'N 2-5 ' indicates two to five residues of any nucleotide) is not believed to vary much among the different members of the STAT family 67 , it is also not clear why STAT1-STAT4 heterodimers uniquely bind to the promoters of Ebi3 and Il12a and transcribe these genes, whereas STAT1-STAT1 and STAT4-STAT4 homodimers do not. This indicates that additional distinguishing differences must exist. These could include unique modifications and/or the recruitment of coactivators via the distinctive combination of STAT1-STAT4 carboxy-terminal transactivation domains that ultimately modifies binding and/or transcription 68, 69 .
Relatively few studies have suggested that heterodimers of STAT proteins can be generated after cytokine signaling. IFN-α can shift a proinflammatory response to an anti-inflammatory response by changing the relative expression and activation of STAT3. A dominant STAT3 response favors the formation of STAT1-STAT3 heterodimers (anti-inflammatory), thereby inhibiting the formation of STAT1-STAT1 homodimers and the biological activities induced in response to STAT1-STAT1 homodimers (inflammatory) 70 . Such observations raise the interesting hypothesis that homodimers of STAT proteins generate mainly proinflammatory responses, whereas heterodimers of STAT proteins drive mainly anti-inflammatory or inhibitory responses 28 . Consistent with that hypothesis is the observation that IL-27 induces both p-STAT3 and p-STAT1, which mediates T cell inhibition, and loss of STAT1 abrogates the suppressive effects of IL-27 by limiting the development of heterodimers of p-STAT1 and p-STAT3 (K.D. Fowler, A. Peters and V.K.K., unpublished data). Clearly, further analysis is needed to assess this; signaling via IL-27R is a particularly interesting candidate for this. As IL-23R induces the activation of STAT3 and STAT4, it is possible that heterodimers are formed, which would undermine this hypothesis. However, p-STAT3 may be generated in excess, such that free IL-23-induced p-STAT3 might be sufficient to mediate the activating effects of IL-23. Alternatively, differences in modifications and/or coactivator recruitment may be critical. Regardless of what proves to be true, further examination of signaling via all the receptors for IL-12 cytokines will probably be extremely informative not only for elucidating how these signals shape diverse functions but perhaps also for establishing paradigms that might guide the understanding of cytokine signaling in general.
Future questions and challenges
Although considerable advances have been made in elucidating the fascinating IL-12 family of cytokines, much remains to be clarified and discovered. Its molecular complexities have also presented substantial obstacles that must be overcome. For example, many mutant mice used for studies in this area lack multiple cytokines, which greatly complicates data interpretation 1 . The generation of mutant lines that lack a single, functional cytokine would be invaluable for detailed in vivo analysis of disease models. Likewise, the development of more specific neutralizing monoclonal antibodies, more-sensitive enzymelinked immunosorbent assays and better antibodies to receptor chains are sorely needed. Finally, IL-35 has proven extremely difficult to produce, which has limited detailed functional analysis.
In addition to the reagent issues noted above, important questions remain. First, are there any more members of this family? Given that IL-35 was discovered only 5 years ago, it is possible that other combinations exist that use either known chains of this cytokine family or as-yet-unknown members. Second, what are the purpose and benefits npg r e v i e w (or limitations) of chain sharing? This could be a mechanism for creating many cytokines with diverse functions from relatively few building blocks. Alternatively, the physiological effects and disease consequences of genetic insults that alter the expression of these proteins may be limited by such incorporation of the proteins into positive and negative regulatory cytokines. Of course, the true importance for this unique feature may remain elusive. Third, what is the extent and physiological effect of competition for chain pairing and binding of cytokine or cytokine receptors? For example, if p40 pairs with p35 to form IL-12, does this limit the availability of p40 to pair with p19, which leads to the generation and secretion of IL-23? Similarly, if IL-35 binds to IL-12Rβ2-gp130, does this limit the availability of the receptors for IL-12 and IL-27? Fourth, how do seemingly similar signals generate diverse outcomes? The observation that part of the IL-35 inhibitory program is mediated by STAT1-STAT4 heterodimers, in contrast to the STAT4-STAT4 homodimers generated by signaling via the IL-12 receptor 29 , presents one possible answer but also raises many questions. For example, do other cytokines with inhibitory properties, such as IL-27, also generate heterodimers, whereas cytokines with proinflammatory properties, such as IL-23, do not? How do heterodimers and homodimers of STAT proteins mediate such diverse functional programs? Fifth, IL-27 has been shown to have both proinflammatory and anti-inflammatory effects. How the same cytokine induces proinflammatory and anti-inflammatory effects, and under which context or combination it does so, must be resolved to allow testing of the neutralization of IL-27 in a therapeutic setting. Finally, could insight into the evolutionary origin of the genes encoding members of the IL-12 family of cytokines and their receptors shed light on the complexity and specificity of their signaling and function?
There are also considerable therapeutic implications and challenges. Neutralization of cytokines and receptor blockade are inherently more challenging for this cytokine family than for others, given its the chain-sharing propensity. However, encouraging proof of principle does exist. For example, monoclonal antibodies specific for IL-12 have been generated (antibody to p70), which raises the possibility that monoclonal antibodies could be raised to epitopes uniquely formed by a particular chain combination or new epitopes revealed by allosteric changes induced by chain pairing. Interestingly, insights into dimer interfaces and modes of chain pairing have identified some clear differences among the members of this cytokine family 19, 22 . This is most evident for IL-35, for which such observations have provided a structural basis for the identification of antibodies to Ebi3 that neutralize IL-35 but not 63) . Finally, as discussed above, the generation of large quantities of members of this cytokine family remains very challenging, which limits their therapeutic potential. Thus, some form of mutagenesis, without loss of biological activity, will probably be required for this. Despite the challenges that remain, it is likely that many surprising and exciting developments lie ahead. 
